|
Kasimova A.R., Tufanova O.S.
Use of apixaban for prevention of a secondary brain stroke in patients with atrial fibrillation
|
№7 / 2024
|
|
Tarzimanova A.I.
Atrial fibrillation: Controversial issues of modern classification, new possibilities of diagnostics and treatment
|
№6 / 2024
|
|
Tatarintseva Z.G., Katushkina Yu.A., Kosmacheva E.D., Babicheva O.V.
Hypokalemia in a patient with heart failure and atrial fibrillation as a predictor of life-threatening arrhythmia
|
№6 / 2024
|
|
Geraskina L.A., Maksimova M.Yu., Fonyakin A.V., Garabova N.I., Burzhunova M.G.
Ischemic stroke in case of atrial fibrillation: Influence of previous therapy at the early functional recovery of the patient
|
№5 / 2024
|
|
Tatarintseva Z.G., Kosmachova E.D.
Correlation between low density lipoproteins / high density lipoproteins ratio and new-onset atrial fibrillation after coronary artery bypass grafting
|
№4 / 2024
|
|
Kasimova A.R., Kolbin A.S.
Pharmacoeconomic analysis of apixaban use for secondary thromboprophylaxis at outpatient stage among oncological patients
|
№1 / 2024
|
|
Prekina V.I., Kunyaeva T.A., Shokina S.V., Samolvina O.G., Skopina Yu.A.
Correction of risk factors in patients with atrial fibrillation
|
№8 / 2023
|
|
Tarzimanova A.I.
Impact of long-term antiarrhythmic therapy on the progression of atrial fibrillation from paroxysmal to permanent form
|
№7 / 2023
|
|
Vorobyeva N.M., Malaya I.P., Alimova E.R., Tkacheva O.N.
Prevention of gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants: Whom? When? How?
|
№5 / 2023
|
|
Adasheva T.V., Samorukova E.I., Gubernatorova E.E., Lobanova E.G., Shahrai N.B.
Anticoagulant therapy for non-valvular atrial fibrillation patients with CHA2DS2-VASC score 1 (regardless of gender): A personalized approach based on risk/benefit analysis
|
№4 / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
Русский
